急性缺血性卒中治疗时间窗的研究进展

doi:10.3969/j.issn.1673-5765.2018.04.012

摘要/Abstract

摘要：

急性缺血性卒中再通治疗是一个多因素、多环节作用的复杂临床干预过程。在长期的临床实践过程中，“时间窗”是一个普遍沿用的概念。早在1996年，3 h内溶栓治疗就已经被证明是急性缺血性卒中的有效治疗手段，然而获得治疗的患者很少，除了治疗时间窗的限制、未能及时就诊等原因，单纯的“时间窗”往往提供不了足够的信息以保证溶栓治疗的安全性和有效性。基础血管病变、侧支循环和缺血耐受的不同，时间窗是否也存在个体差异呢？随着神经影像技术的发展与进步，20多年来国内外学者一直致力于延长卒中治疗时间窗等方面的研究。

文章导读： “争分夺秒”是卒中治疗恒定主题，“时间窗”却不是恒定的数字，其概念在不断与时俱进。

关键词: 时间窗; 静脉溶栓; 血管内治疗; 急性缺血性卒中

Abstract:

Recanalization treatment for acute ischemic stroke is a complicated clinical intervention process, which involves multiple factors and points. Over a long period of time, the concept of “Time Window” is widely used in clinical practice. The efficacy and safety of thrombolytic therapy administered within 3 hours of symptom onset in the treatment of acute ischemic stroke had been proved in 1996. However, beyond the limit of the therapeutic time window and late to medical attention, the safety and validity of recanalization treatment for acute ischemic stroke cannot be ensured by the only “Time Window”. Is there any individual difference in “Time window” based on the different baseline cerebral arterial lesion, collateral circulation and ability of ischemic stroke? With the development and progress of neuroimaging technology, scholars home and abroad have been working on how to extend the therapeutic time window over the past 20 years.

Key words: Time window; Intravenous thrombolysis; Endovascular therapy; Acute ischemic stroke

李威, 刘新峰. 急性缺血性卒中治疗时间窗的研究进展[J]. 中国卒中杂志, 2018, 13(04): 364-371.

参考文献

[1] WANG Y，LIAO X，ZHAO X，et al. Using

recombinant tissue plasminogen activator to treat

acute ischemic stroke in China：analysis of the

results from the Chinese National Stroke Registry

（CNSR）[J]. Stroke，2011，42（6）：1658-1664.

[2] LIU L，WANG D，WONG K S，et al. Stroke and

stroke care in China：huge burden，significant

workload，and a national priority[J]. Stroke，2011，42

（12）：3651-3654.

[3] The National Institute of Neurological Disorders

and Stroke rt-PA Stroke Study Group. Tissue

plasminogen activator for acute ischemic stroke[J].

N Engl J Med，1995，333（24）：1581-1587.

[4] FONAROW G C，SMITH E E，SAVER J L，et

al. Timeliness of tissue-type plasminogen

activator therapy in acute ischemic stroke：patient

characteristics，hospital factors，and outcomes

associated with door-to-needle times within 60

minutes[J]. Circulation，2011，123（7）：750-758.

[5] POWERS W J，DERDEYN C P，BILLER J，et al.

2015 American Heart Association/American Stroke

Association Focused Update of the 2013 Guidelines

for the Early Management of Patients With Acute

Ischemic Stroke Regarding Endovascular Treatment：

A Guideline for Healthcare Professionals From

the American Heart Association/American Stroke Association[J]. Sroke，2015，46（10）：3020-3035.

[6] HERRERA M，GÁLLEGO J，MUÑOZ R，et al.

Reperfusion in acute ischaemic stroke：present and

future[J]. An Sist Sanit Navar，2008，31（Suppl 1）：

31-46.

[7] ASTRUP J，SIESJÖ B K，SYMON L. Thresholds in

cerebral ischemia-the ischemic penumbra[J]. Stroke，

1981，12（6）：723-725.

[8] 吴江. 经病学[M]. 2版. 北京：人民卫生出版社，2010：

158-166.

[9] WAHLGREN N，AHMED N，DÁVALOS A，et

al. Thrombolysis with alteplase for acute ischaemic

stroke in the Safe Implementation of Thrombolysis

in Stroke-Monitoring Study（SITS-MOST）：an

observational study[J]. Lancet，2007，369（9558）：

275-282.

[10] HACKE W，KASTE M，FIESCHI C，et al.

Intravenous thrombolysis with recombinant tissue

plasminogen activator for acute hemispheric stroke.

The European Cooperative Acute Stroke Study

（ECASS）[J]. JAMA，1995，274（13）：1017-1025.

[11] HACKE W，KASTE M，FIESCHI C，et al.

Randomised double-blind placebo-controlled

trial of thrombolytic therapy with intravenous

alteplase in acute ischaemic stroke（ECASS Ⅱ）.

Second European-Australasian Acute Stroke Study

Investigators[J]. Lancet，1998，352（9136）：1245-

1251.

[12] CLARK W M，WISSMAN S，ALBERS G W，et

al. Recombinant tissue-type plasminogen activator

（Alteplase）for ischemic stroke 3 to 5 hours

after symptom onset. The ATLANTIS Study：a

randomized controlled trial. Alteplase Thrombolysis

for Acute Noninterventional Therapy in Ischemic

Stroke[J]. JAMA，1999，282（21）：2019-2026.

[13] HACKE W，KASTE M，BLUHMKI E，et al.

Thrombolysis with alteplase 3 to 4.5 hours after

acute ischemic stroke[J]. N Engl J Med，2008，359

（13）：1317-1329.

[14] WAHLGREN N，AHMED N，DÁVALOS A，et

al. Thrombolysis with alteplase 3-4.5 h after acute

ischaemic stroke（SITS-ISTR）：an observational

study[J]. Lancet，2008，372（9646）：1303-1309.

[15] IST-3 collaborative group，SANDERCOCK P，

WARDLAW J M，et al. The benefits and harms of

intravenous thrombolysis with recombinant tissue

plasminogen activator within 6 h of acute ischaemic

stroke（the third international stroke trial [IST-3]）：

a randomised controlled trial[J]. Lancet，2012，379

（9834）：2352-2363.

[16] ALBERS G W，THIJS V N，WECHSLER L，et

al. Magnetic resonance imaging profiles predict

clinical response to early reperfusion：the diffusion

and perfusion imaging evaluation for understanding

stroke evolution（DEFUSE）study[J]. Ann Neurol，

2006，60（5）：508-517.

[17] DAVIS S M，DONNAN G A，PARSONS M W，et

al. Effects of alteplase beyond 3 h after stroke in

the Echo planar Imaging Thrombolytic Evaluation

Trial（EPITHET）：a placebo-controlled randomised

trial[J]. Lancet Neurol，2008，7（4）：299-309.

[18] HACKE W，ALBERS G，AI-RAWI Y，et al. The

Desmoteplase in Acute Ischemic Stroke Trial

（DIAS）：a phase Ⅱ MRI-based 9-hour window

acute stroke thrombolysis trial with intravenous

desmoteplase[J]. Stroke，2005，36（1）：66-73.

[19] UYTTENBOOGAART M，DE KEYSER

J，LUIJCKX G J，et al. Thrombolysis for acute

ischemic stroke[J]. Curr Top Med Chem，2009，9

（14）：1285-1290.

[20] HACKE W，FURIAN A J，AI-RAWI Y，et al.

Intravenous desmoteplase in patients with acute

ischaemic stroke selected by MRI perfusiondiffusion

weighted imaging or perfusion CT（DIAS-

2）：a prospective，randomised，double-blind，

placebo-controlled study[J]. Lancet Neurol，2009，8

（2）：141-150.

[21] ALBERS G W，VON KUMMER R，TRUELSEN T，

et al. Safety and efficacy of desmoteplase given 3-9

h after ischaemic stroke in patients with occlusion

or high-grade stenosis in major cerebral arteries

（DIAS-3）：a double-blind，randomised，placebocontrolled

phase 3 trial[J]. Lancet Neurol，2015，14

（6）：575-584.

[22] DEL ZOPPO G J，HIGASHIDA R T，FURIAN

A J，et al. PROACT：a phase II randomized trial

of recombinant pro-urokinase by direct arterial

delivery in acute middle cerebral artery stroke.

PROACT Investigators. Prolyse in Acute Cerebral

Thromboembolism[J]. Stroke，1998，29（1）：4-11.

[23] FURLAN A，HIGASHIDA R，WECHSLER L，et al.

Intra-arterial prourokinase for acute ischemic stroke.

The PROACT Ⅱ study：a randomized controlled trial.

Prolyse in Acute Cerebral Thromboembolism[J].

JAMA，1999，282（21）：2003-2011.

[24] OGAWA A，MORI E，MINEMATSU K，et

al. Randomized trial of intraarterial infusion of

urokinase within 6 hours of middle cerebral artery

stroke：the middle cerebral artery embolism local

fibrinolytic intervention trial（MELT）Japan[J].

Stroke，2007，38（10）：2633-2639.

[25] BRODERICK J P，PALESCH Y Y，DEMCHUK A M，et al. Endovascular therapy after intravenous t-PA

versus t-PA alone for stroke[J]. N Engl J Med，2013，

368（10）：893-903.

[26] KIDWELL C S，JAHAN R，GORNBEIN J，et al. A

trial of imaging selection and endovascular treatment

for ischemic stroke[J]. N Engl J Med，2013，368（10）：

914-923.

[27] CICCONE A，VALVASSORI L，NICHELATTI

M，et al. Endovascular treatment for acute ischemic

stroke[J]. N Engl J Med，2013，368（10）：904-913.

[28] BERKHEMER O A，FRANSEN P S，BEUMER D，

et al. A randomized trial of intraarterial treatment

for acute ischemic stroke[J]. N Engl J Med，2015，372

（1）：11-20.

[29] CAMPBELL B C，MITCHELL P J，KLEINIG T J，

et al. Endovascular therapy for ischemic stroke with

perfusion-imaging selection[J]. N Engl J Med，2015，

372（11）：1009-1018.

[30] SAVER J L，GOYAL M，BONAFE A，et al. Stentretriever

thrombectomy after intravenous t-PA vs.

t-PA alone in stroke[J]. N Engl J Med，2015，372

（24）：2285-2295.

[31] JOVIN T G，CHAMORRO A，COBO E，et al.

Thrombectomy within 8 hours after symptom onset

in ischemic stroke[J]. N Engl J Med，2015，372（24）：

2296-2306.

[32] GOYAL M，DEMCHUK A M，MENON B K，et

al. Randomized assessment of rapid endovascular

treatment of ischemic stroke[J]. New Engl J Med，

2015，372（11）：1019-1030.

[33] SAVER J L，GOYAL M，VAN DER LUGT A，et al.

Time to treatment with endovascular thrombectomy

and outcomes from ischemic stroke：a metaanalysis[

J]. JAMA，2016，316（12）：1279-1288.

[34] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，

et al. Thrombectomy 6 to 24 hours after stroke with

a mismatch between deficit and infarct[J]. N Engl J

Med，2018，378（1）：11-21.